Primary biliary cirrhosis secondary prevention

Jump to navigation Jump to search

Primary Biliary Cirrhosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Primary Biliary Cirrhosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Primary biliary cirrhosis secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Primary biliary cirrhosis secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Primary biliary cirrhosis secondary prevention

CDC on Primary biliary cirrhosis secondary prevention

Primary biliary cirrhosis secondary prevention in the news

Blogs on Primary biliary cirrhosis secondary prevention

Directions to Hospitals Treating Primary biliary cirrhosis

Risk calculators and risk factors for Primary biliary cirrhosis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:


Overview

There are no established measures for the secondary prevention of [disease name].

OR

Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].

Secondary Prevention

  • Effective measures for the secondary prevention of primary biliary cirrhosis include:
    • Follow up with liver function tests every 3 to 6 months.
    • Follow up with thyroid status annually.
    • Follow up with upper GI endoscopy to assess for development of varices every 2-3 years.
    • Follow up with bone mineral density every 2-4 years, depending upon the baseline density and severity of cholestasis.
    • Follow up with fat-soluble vitamin levels (Vitamin A,D&K) annually in patients with bilirubin >2mg/dl.
    • Follow up with ultrasound and alpha-fetoprotein levels to screen for hepatocellular carcinoma every 6 to12 months among aged men and patients with underlying cirrhosis.

References

Template:WH Template:WS